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Abstract
In addition to the monographs which were published last
year by the working group ‘‘Drug Monitoring’’ of the
Swiss Society of Clinical Chemistry (SSCC) w1x, new
monographs have been written. The aim of these mono-
graphs is to give an overview of the most important infor-
mation necessary for ordering a drug analysis or inter-
preting the results. Therefore, the targeted readers
comprise laboratory health professionals and all receiv-
ers of laboratory reports. There is information provided
on the indication for therapeutic drug monitoring, protein
binding, metabolic pathways and enzymes involved,
elimination half-life and elimination routes, and on ther-
apeutic or toxic concentrations.
Preanalytical considerations are of particular impor-
tance for therapeutic drug monitoring. Therefore, infor-
mation is provided regarding a reasonable timing for the
determination of drug concentrations as well as steady-
state concentrations after changing the dose. Further-
more, the stability of the drug and its metabolite(s) after
blood sampling is described. For readers with a specific
interest in drug analysis, references to important
publications are given.
*Correspondence: PD Dr. Katharina Rentsch, Universita¨tsSpital
Zu¨rich, Institut fu¨r Klinische Chemie, Ra¨mistraße 100,
8091 Zu¨rich, Switzerland
Phone: q41 44 255 22 90
Fax: q41 44 255 45 90
E-mail: rentsch@ikc.unizh.ch
The number of monographs will be continuously
enlarged. The updated files are presented on the home-
page of the SSCC (www.sscc.ch).
We hope that these monographs are helpful and look
forward to receiving comments from the audience.
Keywords: cyclosporine A; haloperidol; lamotrigine; mir-
tazepine; mycophenolate; paroxetine; phenobarbital; ser-
tralin; valproic acid.
Zusammenfassung
In Erga¨nzung zu den im letzten Jahr publizierten Arznei-
mittelmonographien der Arbeitsgruppe Medikamente der
Schweizerischen Gesellschaft fu¨r Klinische Chemie
(SGKC) w1x sind nun weitere Monographien erstellt wor-
den. Ziel dieser Monographien ist es, dem Labormedizi-
ner bzw. dem Empfa¨nger der Befunde eine U¨bersicht
u¨ber die wichtigsten Informationen zu geben, die fu¨r die
Veranlassung einer Analyse bzw. fu¨r die Interpretation der
Resultate hilfreich sind.
Es werden klinisch-pharmakologische Angaben wie
zum Beispiel Indikation fu¨r das Therapeutic Drug Moni-
toring, Proteinbindungen, Metabolisierungswege und
daran beteiligte Enzyme, Halbwertszeiten und Elimina-
tionswege der Muttersubstanz sowie Informationen zu
therapeutischen bzw. toxischen Bereichen zur Verfu¨gung
gestellt.
Da die Pra¨analytik gerade beim Therapeutic DrugMon-
itoring eine wichtige Rolle spielt, werden auch hier Anga-
ben gemacht, zu welchem Zeitpunkt eine Bestimmung
der Arzneimittelkonzentration sinnvoll ist und wann, nach
einer Dosisa¨nderung, der ‘‘steady-state’’ erreicht ist. Au-
ßerdem werden Informationen zur Stabilita¨t der Medika-
mente bzw. ihrer Metaboliten nach der Blutentnahme
gegeben. Fu¨r die interessierten Leser sind die verwen-
deten Referenzen als Zitate aufgefu¨hrt.
Die Zahl der Monographien wird fortlaufend erga¨nzt.
Die aktuellsten Versionen der Monographien sind auf der
Homepage der SGKC abrufbar (www.sscc.ch).
Wir hoffen, dass Ihnen diese Monographien imUmgang
mit dem Therapeutic Drug Monitoring hilfreich sein wer-
den und freuen uns u¨ber Kommentare und Bemerkungen.
Schlu¨sselwo¨rter: Ciclosporin A; Haloperidol; Lamotrigin;
Mirtazepin; Mycophenolat; Paroxetin; Phenobarbital;
Sertralin; Valproinsa¨ure.
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Cyclosporine
General
• Class of the drug Immunosuppressants
• Synonym(s)
• Common trade name(s) in Germany Cicloral HEXAL, Immunosporin,
Sandimmun, Sandimmun Optoral
• Conversion factors mg/L = 0.83 s nmol/L
nmol/L = 1.20 s mg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance,
side effects, suspicion of toxicity
• Protein binding 41–58% localized in erythrocytes; in plasma 90%
bound to proteins, mainly lipoproteins
• Elimination half-life 5–18 h
• Volume of distribution 3–5 L/kg
• Metabolism
– Main metabolic pathways CYP3A4
– Active metabolite(s) AM1 and AM9 have about 10% of the activity of
cyclosporine
– Inhibitor or inducer of the No
cytochrome P450 system?
– Other significant P-glycoprotein substrate and inducer (e.g. St. John’s Worth)
pharmacokinetic interactions
• Elimination of parent drug Hepatic )94%, renal -6%
• Typical therapeutic range Dependent on combination therapy and indication
• Potentially toxic concentration )500 mg/L (C0)
Pre-analytics
• Time to steady-state from beginning ;2 days
of treatment or change of posology
• Time for blood sampling Before next dose at steady state (C0) or 2 h after
administration (C2)
• Type(s) of sample Whole blood on EDTA
• Stability 5 days at 258C
References • Arzneimittelkompendium Schweiz, Basel: Documed 2005.
• Armstrong VW, Oellerich M. New developments in the
immunosuppressive drug monitoring of cyclosporine,
tacrolimus, and azathioprine. Clin Biochem 2001;34:9–16.
• Holt DW, Armstrong VW, Griesmacher A, Morris RG,
Napoli KL, Shaw L. International Federation of Clinical
Chemistry/International Association of Therapeutic Drug
Monitoring. Therap Drug Monit 2002;24:59–67.
• Kelly P, Kahan BD. Metabolism of immunosuppressant
drugs. Curr Drug Metabol 2002;3:275–87.
• Macphee IA, Fredericks S, Tai T, Syrris P, Carter N,
Johnston A, et al. Tacrolimus pharmacogenetics:
polymorphisms associated with expression of cytochrome
p4503A5 and p-glycoprotein correlate with dose
requirement. Transplantation 2002;74:1486–9.
• Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in
human MDR1 (p-glycoprotein): recent advances and clinical
relevance. Clin Pharmacol Ther 2004;75:13–33.
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Haloperidol
General
• Class of the drug Neuroleptics
• Synonym(s)
• Common trade name(s) in Germany Haldol, Haldol decanoas
• Conversion factors mg/L = 2.66 s nmol/L
nmol/L = 0.38 s mg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, side effects,
suspicion of toxicity
• Protein binding 92%
• Elimination half-life 24 h (12–38 h)
• Volume of distribution 7.9"2.5 L/kg
• Metabolism
– Main metabolic pathways CYP3A4, CYP2D6 and reduction
– Active metabolite(s) None
– Inhibitor or inducer of the Reduced haloperidol (metabolite; inhibits CYP2D6)
cytochrome P450 system?
– Other significant pharmacokinetic None
interactions
• Elimination of parent drug Mainly hepatic
• Typical therapeutic range 3.8–38.0 mg/L (10–100 nmol/L)
• Potentially toxic concentration 49.4 mg/L ()130 nmol/L)
Pre-analytics
• Time to steady-state from beginning of ;5 days
treatment or change of posology
• Time for blood sampling Before next dose at steady state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
References • Arzneimittelkompendium Schweiz, Basel: Documed 2005.
• Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I,
Gerlach M, et al. The AGNP-TDM expert group consensus
guidelines: therapeutic drug monitoring in
psychiatry. Pharmacopsychiatry 2004;37:243–65.
• Helle A, Peterson A. Therapeutic drug monitoring of
haloperidol, perphenazine, and zuclopenthixol in serum by
a fully automated sequential solid phase extraction
followed by high-performance liquid chromatography.
Ther Drug Monit 2001;23:157–62.
• Llerena A, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol
disposition is dependent on debrisoquine hydroxylation
phenotype. Ther Drug Monit 1992;14:92–7.
• Pan L, Rosseel MT, Belpaire FM. Comparison of two
high-performance liquid chromatographic methods for
monitoring plasma concentrations of haloperidol and
reduced haloperidol. Ther Drug Monit 1998;20:224–30.
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Lamotrigine
General
• Class of the drug Antiepileptics
• Synonym(s)
• Common trade name(s) in Germany Lamictal, elmendos
• Conversion factors mg/L = 3.90 s mmol/L
mmol/L = 0.256 s mg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance
• Protein binding 55%
• Elimination half-life 25 h (60 h in presence of valproate, 15 h in presence of
phenytoin, carbamazepine or phenobarbital)
• Volume of distribution 1–1.4 L/kg
• Metabolism
– Main metabolic pathways N-glucuronidation
– Active metabolite(s) None
– Inhibitor or inducer of the Not known
cytochrome P450 system?
– Other significant • Coadministration with valproic acid results in decreased
pharmacokinetic interactions elimination of lamotrigine
• Coadministration with enzyme inducing drugs, including
carbamazepine, phenytoin and phenobarbital,
results in increased elimination
• Elimination of parent drug Mainly hepatic, renal 10%
• Typical therapeutic range 3–14 mg/L (12–56 mmol/L)
• Potentially toxic concentration Not known
Pre-analytics
• Time to steady-state from beginning of 4–5 days
treatment or change of posology
• Time for blood sampling Before next dose at steady state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
References • Arzneimittelkompendium Schweiz, Basel: Documed 2005.
• Johannessen SI, Battino D, Berry DJ, Bialer M, Kramer G,
Tomson T, et al. Therapeutic drug monitoring of the newer
antiepileptic drugs. Ther Drug Monit 2003;25:347–63.
• Morris RG, Black AB, Harris AL, Batty AL, Sallustio BC.
Lamotrigine and therapeutic drug monitoring: retrospective
survey following the introduction of a routine service.
Br J Clin Pharmacol 1998;46:547–51.
• Morris RG, Lee MY, Cleanthous X, Black AB. Long-term
follow-up using a higher target range for lamotrigine
monitoring. Ther Drug Monit 2004;26:626–32.
• Neels HM, Sierens AC, Naelaerts K, Scharpe SL, Hatfield GM,
Lambert WE. Therapeutic drug monitoring of old
and newer anti-epileptic drugs. Clin Chem Lab Med
2004;42:1228–55.
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Mirtazapine
General
• Class of the drug Antidepressants
• Synonym(s)
• Common trade name(s) Remergil
in Germany
• Conversion factors
Mirtazapine: mg/L = 3.77 s nmol/L
nmol/L = 0.26 s mg/L
Desmethylmirtazapine: mg/L = 3.97 s nmol/L
nmol/L = 0.25 s mg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, side effects,
suspicion of toxicity
• Protein binding 85%
• Elimination half-life 20–40 h
• Volume of distribution 4.5 L/kg
• Metabolism
– Main metabolic pathways CYP3A4, CYP2D6, CYP1A2
– Active metabolite(s) Desmethylmirtazapine
– Inhibitor or inducer of the No
cytochrome P450 system?
– Other significant pharmacokinetic None
interactions
• Elimination of parent drug Hepatic )80%, renal -20%
• Typical therapeutic range
Mirtazapine: 10.4–31.2 mg/L
(40–120 nmol/L)
Desmethylmirtazapine: 5.0–20.0 mg/L (20–80 nmol/L)
• Potentially toxic concentration Not known
Pre-analytics
• Time to steady-state of treatment ;5 days from beginning
or change of posology
• Time for blood sampling Before next dose at steady state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
References • Arzneimittelkompendium Schweiz, Basel: Documed 2005.
• Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I,
Gerlach M, et al. The AGNP-TDM expert group consensus
guidelines: therapeutic drug monitoring in psychiatry.
Pharmacopsychiatry 2004;37:243–65.
• Delbressine LP, Moonen ME, Kaspersen FM, Wagenaars GN,
Jacobs PL, Timmer CJ, et al. Pharmacokinetics and
biotransformation of mirtazapine in human volunteers.
Clin Drug Invest 1998;15:45–56.
• Pistos C, Koutsopoulou M, Panderi I. A validated liquid chromato-
graphic tandem mass spectrometric method for the determination
of mirtazapine and desmethylmirtazapine in human plasma:
application to a pharmacokinetic study. Anal Chim Acta
2004;514:15–26.
• Shams M, Hiemke C, Hartter S. Therapeutic drug monitoring of
the antidepressant mirtazapine and its N-demethylated metabolite
in human serum. Ther Drug Monit 2004;26:78–84.
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Mycophenolate (MPA)
General
• Class of the drug Immunosuppressants
• Synonym(s) Mycophenolic acid
• Common trade name(s) in Germany CellCept, Myfortic
• Conversion factors mg/L = 3.12 s mmol/L
mmol/L = 0.32 s mg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, symptoms of rejection or toxicity
• Protein binding 97–99% (mainly to albumin)
• Elimination half-life 17 h
• Volume of distribution 4 L/kg
• Metabolism:
– Main metabolic pathways Glucuroconjugation to form 7-O-MPA-glucuronide (MPAG);
two other metabolites are 7-O-glucoside-MPA
and acylglucuronide-MPA (AcMPAG)
– Active metabolite(s) AcMPAG
– Inhibitor or inducer of the No
cytochrome P450 system?
– Other significant pharmacokinetic None
interactions
• Elimination of parent drug Mainly hepatic
• Typical therapeutic range Dependent on combination therapy and indication
• Potentially toxic concentration )10 mg/L
Pre-analytics
• Time to steady-state from beginning of ;3 days
treatment or change of posology
• Time for blood sampling Before next dose at steady state or at different time points
for the determination of the area-under-the-curve (AUC)
• Type(s) of sample Plasma on EDTA
• Stability 5 days at 258C
Remarks • Mycophenolate mofetil (MMF) is a prodrug for the active MPA.
• Most immunoassays cross-react with the active metabolite.
• The AUC correlates better with the inhibition of the inosine
monophosphate dehydrogenase (IMPDH) than the trough level.
References • Arzneimittelkompendium Schweiz, Basel: Documed 2005.
• Holt DW, Armstrong VW, Griesmacher A, Morris RG,
Raymond G, Napoli K, et al. International Federation of
Clinical Chemistry/International Association of
Therapeutic Drug Monitoring and Clinical Toxicology
working group on immunosuppressive drug monitoring.
Therap Drug Monit 2002;24:59–67.
• Shaw LM, Nicholls A, Hale M, Holt DW,
Venkataramanan R, Haley J, et al. Therapeutic drug
monitoring of mycophenolic acid: A consensus panel.
Clin Biochem 1998;31:317–22.
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Paroxetine
General
• Class of the drug Antidepressants
• Synonym(s)
• Common trade name(s) in Germany Seroxat, Tagonis
• Conversion factors mg/L = 3.03 s nmol/L
nmol/L = 0.33 s mg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, side effects,
suspicion of toxicity
• Protein binding 95%
• Elimination half-life 24 h (6–71 h)
• Volume of distribution 17 L/kg
• Metabolism
– Main metabolic pathways CYP2D6 and other CYP enzymes
– Active metabolite(s) None
– Inhibitor or inducer of the Inhibitor of CYP2D6
cytochrome P450 system?
– Other significant Not known
pharmacokinetic interactions
• Elimination of parent drug Hepatic 36%, renal 64%
• Typical therapeutic range 39.6–122 mg/L (120–370 nmol/L)
• Potentially toxic concentration Not known
Pre-analytics
• Time to steady-state from beginning ;5 days
of treatment or change of posology
• Time for blood sampling Before next dose at steady state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
References • Arzneimittelkompendium Schweiz, Basel: Documed 2005.
• Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I,
Gerlach M, et al. The AGNP-TDM expert group
consensus guidelines: therapeutic drug monitoring in
psychiatry. Pharmacopsychiatry 2004;37:243–65.
• Foglia JP, Sorisio D, Kirshner M, Pollock BG.
Quantitative determination of paroxetine in plasma by
high-performance liquid chromatography
and ultraviolet detection. J Chrom B 1997;693:147–51.
• Linder MW, Keck PE Jr. Standards of laboratory practice:
antidepressant drug monitoring. National
Academy of Clinical Biochemistry. Clin Chem
1998;44:1073–84.
• Lucca A, Gentilini G, Lopez-Silva S, Soldarini A.
Simultaneous determination of human plasma levels of
four selective serotonin reuptake inhibitors by
high-performance liquid chromatography.
Ther Drug Monit 2000;22:271–6.
• Montgomery SA. Efficacy of long-term treatment of
depression. J Clin Psychiatry 1996;57:24–30.
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Phenobarbital
General
• Class of the drug Antiepileptics
• Synonym(s)
• Common trade name(s) in Germany Luminal, Luminaletten
• Conversion factors mg/L = 4.31 s mmol/L
mmol/L = 0.232 s mg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance,
side effects, suspicion of toxicity
• Protein binding 50% (to albumin)
• Elimination half-life 50–150 h (varies with age, urinary pH, hepatic and
renal function)
• Volume of distribution 0.7 L/kg
• Metabolism
– Main metabolic pathways Hydroxylation by P450 cytochromes to form
p-hydroxyphenobarbital followed by glucuro- or
sulfoconjugation
– Active metabolite(s) None
– Inhibitor or inducer of the Inducer of cytochromes CYP3A4 and CYP2C9 (also
cytochrome P450 system? auto-induction)
– Other significant Interaction with valproic acid (phenobarbital levels
pharmacokinetic interactions increase)
• Elimination of parent drug Hepatic 75%, renal 25%
• Typical therapeutic range 15–40 mg/L (64–172 mmol/L)
• Potentially toxic concentration )50 mg/L ()216 mmol/L)
Pre-analytics
• Time to steady-state from beginning 10–30 days
of treatment or change of posology
• Time for blood sampling Before next dose at steady state
• Type(s) of sample Serum or plasma
• Stability 48 h at 48C (for longer conservation, freeze at -208C)
References • Arzneimittelkompendium Schweiz, Basel: Documed 2005.
• Schweizerische Gesellschaft fu¨r Klinische Pharmakologie
und Toxikologie, Grundlagen der Arzneimitteltherapie
(16. Auflage), Basel: Documed, 2005.
• Neels HM, Sierens AC, Naelaerts K, Scharpe SL,
Hatfield GM, Lambert WE. Therapeutic drug monitoring
of old and newer anti-epileptic drugs.
Clin Chem Lab Med 2004;42:1228–55.
• Warner A, Privitera M, Bates D. Standards of
laboratory practice: antiepileptic drug monitoring.
Clin Chem 1998;44:1085–95.
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Sertraline
General
• Class of the drug Antidepressants
• Synonym(s)
• Common trade name(s) in Germany Gladem, Zoloft
• Conversion factors mg/L = 3.26 s nmol/L
nmol/L = 0.31 s mg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance,
side effects, suspicion of toxicity
• Protein binding 98%
• Elimination half-life 22–36 h for sertraline
62–104 h for N-desmethylsertraline
• Volume of distribution )20 L/kg
• Metabolism
– Main metabolic pathways CYP3A4, CYP2D6, CYP2B6, CYP2C9
– Active metabolite(s) N-Desmethylsertraline
– Inhibitor or inducer of the Weak inhibitor of CYP2D6 and CYP3A4
cytochrome P450 system?
– Other significant None
pharmacokinetic interactions
• Elimination of parent drug Hepatic 50%, renal 50%
• Typical therapeutic range 12.4–62.0 mg/L (40–200 nmol/L)
• Potentially toxic concentration Not known
Pre-analytics
• Time to steady-state from ;5 days
beginning of treatment or change of
posology
• Time for blood sampling Before next dose at steady state
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
References • Arzneimittelkompendium Schweiz, Basel: Documed 2005.
• Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I,
Gerlach M, et al. The AGNP-TDM expert group
consensus guidelines: therapeutic drug monitoring in
psychiatry. Pharmacopsychiatry 2004;37:243–65.
• Linder MW, Keck PE Jr. Standards of laboratory practice:
antidepressant drug monitoring. National Academy of
Clinical Biochemistry. Clin Chem 1998;44:1073–84.
• Lucca A, Gentilini G, Lopez-Silva S, Soldarini A.
Simultaneous determination of human plasma levels of
four selective serotonin reuptake inhibitors by high-
performance liquid chromatography. Ther Drug Monit
2000;22:271–6.
• Montgomery SA. Efficacy of long-term treatment of
depression. J Clin Psychiatry 1996;57:24–30.
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Valproic acid
General
• Class of the drug Antiepileptics
• Synonym(s) Valproate
• Common trade name(s) in Germany Convulex, Ergenyl, Orfiril
• Conversion factors mg/L = 6.93 s mmol/L
mmol/L = 0.144 s mg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, verification of compliance, side
effects, suspicion of toxicity
• Protein binding 85 to 95% at low concentration, decreases to 70% with
higher dosing (mainly to albumin)
• Elimination half-life 5–20 h
• Volume of distribution 0.13–0.15 L/kg
• Metabolism
– Main metabolic pathways Glucuroconjugation by uridine diphosphate
glucuronosyltransferases (;50%), mitochondrial
b-oxydation (;40%) and P-450 oxidation (;10%)
– Active metabolite(s) Present but not clinically relevant
– Inhibitor or inducer of the Inhibitor of cytochromes CYP2C9 and CYP3A4
cytochrome P450 system?
– Other significant Numerous interactions, in particular with other
pharmacokinetic interactions antiepileptics (e.g. phenytoin, lamotrigine, phenobarbital)
• Elimination of parent drug Hepatic )95%, renal -3%
• Typical therapeutic range 50–100 mg/L (347–693 mmol/L)
• Potentially toxic concentration )120 to 150 mg/L ()832–1040 mmol/L)
Pre-analytics
• Time to steady-state from beginning 2–4 days
of treatment or change of posology
• Time for blood sampling Before next dose at steady state
• Type(s) of sample Serum or plasma
• Stability 48 h at 48C (for longer conservation, freeze at -208C)
Remarks In patients with renal insufficiency the free valproic
acid concentration should be determined due to
reduced protein binding.
References • Arzneimittelkompendium Schweiz, Basel: Documed 2005.
• Schweizerische Gesellschaft fu¨r Klinische Pharmakologie
und Toxikologie, Grundlagen der Arzneimitteltherapie
(16. Auflage), Basel: Documed, 2005.
• DeVane CL. Pharmacokinetics, drug interactions, and
tolerability of valproate. Psychopharmacol Bull
2003;37(Suppl 2):25–42.
• Regenthal R, Krueger M, Koeppel C, Preiss R.
Drug levels: therapeutic and toxic serum/plasma
concentrations of common drugs. J Clin Monit Comput
1999;15:529–44.
• Warner A, Privitera M, Bates D. Standards of
laboratory practice: antiepileptic drug monitoring. Clin
Chem 1998;44:1085–95.
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